drug adverse effects of long-acting beta-adrenergic receptor agonists
Jump to navigation
Jump to search
Adverse effects
- when taken without an inhaled corticosteroid, may increase risk for death[2][3][4]*
- Advair Diskus, Foradil Aerolizer, & Serevent Diskus may increase the chance of severe asthma episodes, & death when those episodes occur
- increased cardiovascular risk in the elderly
- highest risk 2-3 weeks after starting treatment[5]
* risk for asthmatics > risk for patients with COPD
More general terms
References
- ↑ FDA Medwatch http://www.fda.gov/medwatch/safety/2005/safety05.htm#LABA
- ↑ 2.0 2.1 FDA advisory panel meeting Joint Meeting of the Pulmonary-Allergy Drugs Advisory Committee, Drug Safety & Risk Management Advisory Committee, and the Pediatric Advisory Committee December 10 & 11, 2008 http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4398b1-00-index.htm
Bateman E et al Effects of adding salmeterol to inhaled corticosteroids on serious asthma-related events. Ann Intern Med. 2008 Jul 1;149(1):33-42. Epub 2008 Jun 3. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/18523132 <Internet> http://www.annals.org/cgi/content/full/0000605-200807010-00229v1
Weiss KB. Drug safety and salmeterol: The controversy continues. Ann Intern Med. 2008 Jul 1;149(1):56-7. Epub 2008 Jun 3. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/18523131 <Internet> http://www.annals.org/cgi/content/full/0000605-200807010-00230v1 - ↑ 3.0 3.1 Prescriber's Letter 16(1): 2009 Safety of Long-Acting Beta-Agonists in Asthma Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=250102&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ 4.0 4.1 Prescriber's Letter 17(4): 2010 New Safety Requirements for Long-Acting Beta-Agonists (LABAs) COMMENTARY: New Safety Requirements for Long-Acting Beta-Agonists (LABAs) COMMENTARY: Childhood Asthma Treatment: The BADGER Study Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=260401&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ 5.0 5.1 Gershon A et al Cardiovascular Safety of Inhaled Long-Acting Bronchodilators in Individuals With Chronic Obstructive Pulmonary Disease. JAMA Intern Med. 2013;():1-9. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/23689820 <Internet> http://archinte.jamanetwork.com/article.aspx?articleid=1689974